OBJECTIVES: M184V in HIV-1 reverse transcriptase is among the most common mutations in patients failing antiretroviral therapy but is found only rarely in cases of transmitted drug resistance. METHODS: To investigate this apparent paradox, we developed an allele-specific real-time PCR (AS-PCR) assay to determine the transmission of M184V in newly infected individuals. RESULTS: M184V transmission may occur to a greater extent than previously thought. Persistence of M184V may commonly involve linkage to other drug resistance mutations. The presence of M184V as a single substitution in newly infected individuals was shown to wane over time, as a likely consequence of reversion and overgrowth by more fit wild-type viruses. CONCLUSIONS: The M184V mutation can be documented in newly infected individuals, and the alternative hypothesis that this substitution might impact on the ability of HIV to be transmitted is unfounded.
OBJECTIVES:M184V in HIV-1 reverse transcriptase is among the most common mutations in patients failing antiretroviral therapy but is found only rarely in cases of transmitted drug resistance. METHODS: To investigate this apparent paradox, we developed an allele-specific real-time PCR (AS-PCR) assay to determine the transmission of M184V in newly infected individuals. RESULTS:M184V transmission may occur to a greater extent than previously thought. Persistence of M184V may commonly involve linkage to other drug resistance mutations. The presence of M184V as a single substitution in newly infected individuals was shown to wane over time, as a likely consequence of reversion and overgrowth by more fit wild-type viruses. CONCLUSIONS: The M184V mutation can be documented in newly infected individuals, and the alternative hypothesis that this substitution might impact on the ability of HIV to be transmitted is unfounded.
Authors: Hong-Tao Xu; Maureen Oliveira; Peter K Quashie; Matthew McCallum; Yingshan Han; Yudong Quan; Bluma G Brenner; Mark A Wainberg Journal: J Virol Date: 2012-05-23 Impact factor: 5.103
Authors: Katy L Garrett; Jingxian Chen; Brian M Maas; Mackenzie L Cottrell; Heather A Prince; Craig Sykes; Amanda P Schauer; Nicole White; Julie B Dumond Journal: J Pharmacol Exp Ther Date: 2018-08-27 Impact factor: 4.030
Authors: Trevor A Crowell; Gustavo H Kijak; Eric Sanders-Buell; Anne Marie O'Sullivan; Afoke Kokogho; Zahra F Parker; John Lawlor; Christina S Polyak; Sylvia Adebajo; Rebecca G Nowak; Stefan D Baral; Merlin L Robb; Manhattan E Charurat; Julie A Ake; Nicaise Ndembi; Sodsai Tovanabutra Journal: Antivir Ther Date: 2019
Authors: J D Baxter; D Dunn; E White; S Sharma; A M Geretti; M J Kozal; M A Johnson; S Jacoby; J M Llibre; J Lundgren Journal: HIV Med Date: 2015-04 Impact factor: 3.180
Authors: Gert U van Zyl; Lisa M Frenkel; Michael H Chung; Wolfgang Preiser; John W Mellors; Jean B Nachega Journal: AIDS Date: 2014-11-28 Impact factor: 4.177
Authors: S Sinha; H Ahmad; R C Shekhar; N Kumar; L Dar; J C Samantaray; S K Sharma; A Bhargava; R M Pandey; R L Mitsuyasu; J L Fahey Journal: AIDS Res Treat Date: 2012-03-15
Authors: J D Baxter; D Dunn; A Tostevin; R L Marvig; M Bennedbaek; A Cozzi-Lepri; S Sharma; M J Kozal; M Gompels; A N Pinto; J Lundgren Journal: HIV Med Date: 2020-12-25 Impact factor: 3.094